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Abstract
Introduction: In healthy carriers of the T allele of the transcription factor 7-like 2 
(TCF7L2), fasting plasma glucagon concentrations are lower compared with those 
with the C allele. We hypothesised that presence of the T allele is associated with a 
diminished glucagon response during hypoglycaemia and a higher frequency of severe 
hypoglycaemia (SH) in type 1 diabetes (T1DM).
Material and methods: This is a post hoc study of an earlier prospective observational study 
of SH and four mechanistic studies of physiological responses to hypoglycaemia. 269 patients 
with T1DM were followed in a one-year observational study. A log-linear negative binomial 
model was applied with events of SH as dependent variable and TCF7L2 alleles as explanatory 
variable. In four experimental studies including 65 people, TCF7L2 genotyping was done and 
plasma glucagon concentration during experimental hypoglycaemia was determined.
Results: Incidences of SH were TT 0.54, TC 0.98 and CC 1.01 episodes per patient-year 
with no significant difference between groups. During experimental hypoglycaemia, the 
TCF7L2 polymorphism did not influence glucagon secretion.
Discussion: Patients with T1DM carrying the T allele of the TCF7L2 polymorphism do not 
exhibit diminished glucagon response during hypoglycaemia and are not at increased 
risk of severe hypoglycaemia compared with carriers of the C allele.
Introduction
Patients with type 1 diabetes are at daily risk of 
events of severe hypoglycaemia (1, 2, 3, 4, 5, 6, 7). 
The distribution of these events is much skewed 
with a minority of subjects accounting for the vast 
majority of episodes (1, 2). Although important risk 
markers for severe hypoglycaemia like hormonal 
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counter-regulatory failure (8) and impaired hypo-
glycaemia awareness (6) have been identified, the 
highly varying inter-individual susceptibility to severe 
hypoglycaemia is largely unexplained. We previously 
speculated whether genetic factors are implicated and 
reported a high rate of severe hypoglycaemia in type 1 
diabetic subjects carrying the common deletion-allele 
of the angiotensin-converting enzyme (ACE) gene that 
confers high enzyme activity in blood and tissues (9). 
This finding has been reproduced in six studies in five 
different populations by four independent research 
groups (10, 11, 12, 13, 14, 15). Schouwenberg and 
coworkers showed in healthy adults that possessing 
the Arg Arg (vs the Gly Gly) polymorphism of the 
β2-adrenergic receptor may to some extent protect 
against the development of hypoglycaemia 
unawareness (16, 17), a major risk indicator of severe 
hypoglycaemia. In contrary Holstein et  al. found no 
association between four genetic polymorphisms 
associated with insulin secretion and risk of severe 
hypoglycaemia in sulfonylurea-treated persons with 
type 2 diabetes (18).
Glucagon is a key player during the first-phase 
hormonal counter-regulation of hypoglycaemia 
(19). In people with type 1 diabetes, the glucagon 
secretory response to hypoglycaemia is initially 
diminished and subsequently lost within a few years 
of the onset of diabetes (20, 21). In the search for 
candidate risk genes for type 2 diabetes, the T allele 
of rs7903146 transcription factor 7-like 2 (TCF7L2) 
has been shown to confer the hitherto strongest 
association with type 2 diabetes, with a per allele odds 
ratio of 1.4 (22, 23, 24). During the efforts to elucidate 
the underlying mechanism, a functional impact of 
the gene variant on glucagon concentrations has 
emerged. Thus, fasting glucagon concentrations were 
reported to be lower in healthy carriers of the T allele 
(approximately 30% of the population (25)) compared 
with those with the C allele (26, 27, 28), whereas 
incremental glucagon secretion after a meal test 
does not differ between the alleles in normal, glucose-
tolerant subjects (29). The extent to which the 
TCF7L2 gene polymorphism influences glucagon 
secretion and/or risk of hypoglycaemia in people with 
type 1 diabetes is unknown.
We explored whether variants of the TCF7L2 gene 
influence the risk of severe hypoglycaemia in people with 
type 1 diabetes. The hypothesis was tested in a cohort 
of patients with type 1 diabetes previously followed for 
one year in an observational prospective study of the 
occurrence of severe hypoglycaemia (14). We also explored 
if variants of the TCF7L2 gene influence the secretion of 
glucagon during experimental hypoglycaemia in healthy 
adults and adult people with type 1 diabetes.
Materials and methods
Epidemiological study
This study is a post hoc study of blood samples collected 
during a prospective study designed to evaluate risk 
markers for severe hypoglycaemia in type 1 diabetes 
(14). Consecutive adult (>18 years of age) outpatients 
with type 1 diabetes for more than two years were 
recruited by mail. Type 1 diabetes was defined by 
insulin treatment from the time of diagnosis and 
non-stimulated C-peptide <300 pmol/L or stimulated 
(venous blood glucose concentration >12 mmol/L) 
C-peptide <600 pmol/L. Pregnant women and subjects 
on haemodialysis or suffering from concomitant 
malignant disease were excluded from participation. 
Clinical characteristics of the participating subjects 
appear from Table 1. Consent to participate was obtained 
from each subject after full explanation of the purpose 
and nature of all procedures used, and the study was 
approved by the Regional Committee on Biomedical 
Research Ethics. Results regarding the association 
between renin–angiotensin system components and 
risk of severe hypoglycaemia have been published 
elsewhere (30, 14).
At baseline, participants were characterised by their 
previous experience of hypoglycaemia. Episodes of 
severe hypoglycaemia were then reported prospectively 
for one year. The events were reported by telephone 
within 24 h and validated according to the triad of 
Whipple as described previously in detail (14). Only 
definite (all three criteria in Whipple’s triad) and 
probable episodes (two criteria in Whipple’s triad) of 
hypoglycaemia were classified as severe hypoglycaemia 
and used in the statistical analysis. These episodes 
were the primary endpoint. Two trained study nurses 
performed structured telephone interviews to establish 
the level of documentation, classify severity and 
explore circumstances of the incidents. Additionally, at 
the end of the follow-up period, severe hypoglycaemia 
was reported retrospectively by questionnaire, and in 
the case of missed reporting by telephone, interviews 
were carried out. Severe hypoglycaemia was defined 
as an episode at which the patient needs assistance 
from another person to restore the blood glucose level. 
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Hypoglycaemia awareness was estimated by a validated 
method based on self-reported ability to perceive 
hypoglycaemia (31). This method has previously been 
validated prospectively (32) and proven clinically 
relevant across language barriers in different populations 
(2, 33). The prevalence of unawareness corresponds 
to the prevalence of impaired awareness according to 
methods with only two categories (31, 5, 6). Data on 
history of diabetes were extracted from medical records 
as described previously (14).
Experimental study
This study is a post hoc study of blood samples collected 
during four previously reported experimental studies. The 
first three were designed to evaluate the effect of activity 
in the renin–angiotensin system on hormonal, cardiac 
and cognitive function parameters during experimental 
hypoglycaemia (34, 35, 36). The fourth study was a 
randomised controlled trial (RCT) designed to evaluate 
the effect of exogenous erythropoietin on cognitive 
function during hypoglycaemia in patients prone to severe 
hypoglycaemia (37). An overview of the four studies is 
available in Table 2. Specific details about the experimental 
protocol, including ethical issues and consent to 
participate, are reported elsewhere (34, 35, 36, 37).
Laboratory analyses
Radioimmunological determination of plasma glucagon 
concentrations was performed using a specific assay as 
described (38). The analytical detection limit was 1 pmol/L 
and intra- and inter-assay coefficients of variation were 
<6% and <15% respectively. Genotyping for TCF7L2 
rs7903146 was performed using allelic discrimination 
performed with an ABI 7900 system (KBioscience, 
Hoddesdon, UK) as described (39). The genotype 
distribution obeyed Hardy–Weinberg equilibrium 
Table 1 Patient characteristics in the total cohort and divided into TCF7L2 genotype.
All TT TC CC Missing genotype P
Number of patients (n; %) 269 (100) 13 (4.8) 89 (33.1) 143 (53.2) 24 (8.9)
 Men (%) 160 (59.5) 10 (76.9) 48 (53.9) 85 (59.4) 17 (70.8) 0.27
 Women (%) 109 (40.5) 3 (23.1) 41 (46.1) 58 (40.6) 7 (29.2)
Age (years) 45.1 ± 13.4
19–84
46.6 ± 10.6
30–67
46.2 ± 14.5
20–84
44.2 ± 13.3
19–83
45.3 ± 11.6
20–64
0.55
BMI (kg/m2) 25.1 ± 3.65
17.7–38.6
25.4 ± 3.83
19.4–33.9
24.6 ± 3.63
17.7–35.6
25.4 ± 3.68
19.5–38.6
25.0 ± 3.52
20.3–34.9
0.32
Duration of diabetes (years) 20.9 ± 11.8
3–56
21.2 ± 9.7
9–38
20.5 ± 12.3
3–55
20.5 ± 11.5
3–56
20.3 ± 13.0
3–50
0.98
Age at diagnosis of diabetes (years) 24.6 ± 14.2
0–70
25.5 ± 13.1
2–43
25.7 ± 15.5
0–60
23.8 ± 13.8
2–70
20.3 ± 13.0
3–50
0.62
HbA1c at entry (%) 8.60 ± 1.22
5.2–14.0
9.1 ± 1.1
7.0–11.1
8.5 ± 1.3
5.2–12.4
8.7 ± 1.2
5.5–14.0
8.38 ± 1.05
7.0–10.8
0.17
C-peptide positive (%)a (pmol/L) 59.9
65 ± 91
0–400
8 (62)
48 ± 55
0–189
56 (63)
84 ± 106
0–400
77 (54)
50 ± 77
0–343
20 (83.3)
90 ± 115
0–383
0.38
0.09
Plasma glucagon (pmol/L) 4.8 ± 3.4 6.2 ± 4.8 4.9 ± 3.6 4.7 ± 3.3 4.7 ± 2.9 0.70
BG ≥ 4 (n = 227 (87%)) 4.9 ± 3.5 6.6 ± 5.3 4.9 ± 3.5 4.8 ± 3.4 4.3 ± 2.7 0.85
BG <4  (n = 35 (13%)) 4.5 ± 3.2 4.7 ± 3.1 5.6 ± 5.0 4.1 ± 2.3 6.0 ± 3.5 0.64
Plasma glucose at entry (mmol/L) 9.9 ± 4.9
0.9–24
8.8 ± 5.2
1–18
10.2 ± 4.7
0.9–23
9.9 ± 5.0
1–24
10.5 ± 5.9
2–25
0.61
Severe hypoglycaemic events per  
patient-year (mean, min–max)
0.96, 0–16 0.54, 0–5 0.97, 0–15 0.99, 0–16 0.67, 0–5
 None (n; %) 179 (66.5) 11 (84.6) 55 (61.8) 95 (66.4) 18 (75.0)
 One (n; %) 43 (16.0) 0 20 (22.5) 21 (14.7) 2 (8.3) 0.24
 More than one (n; %) 47 (17.5) 2 (14.4) 14 (15.7) 27 (18.9) 4 (16.7)
Awareness (%)
 Normal 44 25.0 38.6 45.1 66.7
 Impaired 44 50.0 50.5 42.3 29.2 0.15
 Unaware 12 25.0 11.4 12.7 4.2
Values are mean (s.d.) or percentage when indicated. Frequency of severe hypoglycaemia is described by mean, min–max and distribution of zero, one or 
more episodes per year. We used one-way ANOVA, chi-square test and Kruskal–Wallis test as appropriate. P values refer to comparisons between TCF7L2 
genotypes (missing genotype group is not included in the statistical assessment). aA subject is classified as C-peptide negative if below the detection limit 
of 10 pmol/L.
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(P > 0.05). HbA1c was measured spectrophotometrically 
(DCA-2000, Bayer; normal range 4.1–6.4%). C-peptide 
levels were measured by radioimmunoassay (Autodelfia, 
Wallac Oy, Turku, Finland). Subjects were classified as 
being C-peptide negative if the value is below 10 pmol/L 
(detection limit of the assay). Measurements of HbA1c, 
C-peptide and glucagon were done at the time of the 
primary studies, except for measurement of glucagon 
in the epidemiological study; genotyping was done 
post hoc. Blood for post hoc laboratory analysis 
was stored at −80°C since the completion of the 
primary studies.
Statistical analyses
No participant appears twice in the epidemiological 
study, or the experimental studies, but some participants 
were included in both the epidemiological study and an 
experimental study.
Epidemiological study As the distribution of 
episodes of severe hypoglycaemia (primary endpoint) 
is very skewed (1, 2), a log-linear negative binomial 
regression model was applied (SPSS: Analyze > Generalized 
Linear Models > Negative Binomial) with events of 
severe hypoglycaemia as dependent variable. First, 
we did univariate analyses with plasma glucagon or 
TCF7L2 genotype as explanatory variables. Secondly, we 
performed a multivariate analysis with adjustment for 
Table 2 Characteristics of the four experimental studies.
Study 1 Study 2 Study 3 Study 4
Reference Hoi-Hansen et al. (35) Due-Andersen et al. (36) Bie-Olsen et al. (34) Kristensen et al. (37)
Study objective To study the effect of 
high or low activity 
of RAS on cognitive 
function and 
hormonal counter 
regulation during 
hypoglycaemia
To study to the effect 
of high or low 
activity of RAS on the 
QT interval and its 
dynamics during 
hypoglycaemia and 
hypoxaemia
To study the effect  
of high or low 
activity of RAS on 
changes in cerebral 
activity during 
hypoglycaemia 
measured with PET
To study the effect  
of treatment with 
EPO on cognitive  
function during 
hypoglycaemia
Population Type 1 diabetes: 9 with 
high and 9 with low 
activity in RAS
Healthy adults: 10 with 
high and 10 with low 
activity in RAS
Healthy adults: 10 with 
high and 10 with low 
activity in RAS
Type 1 diabetes:  
Prone to severe 
hypoglycaemia
Induction of hypoglycaemia Standardised  
intravenous insulin 
infusion. No glucose 
was infused
Subcutaneously 
administered insulin
Standardised  
intravenous insulin 
infusion. No glucose 
was infused
Intravenous  
hypoglycaemic clamp
N 18 20 20 11
Mean plasma glucose 
during hypoglycaemia, 
mean (s.d.) (mmol/L)
2.5 (0.3) 2.8 (0.3) 2.2 (0.4) 2.2 (0.1) EPO-day
2.2 (0.2) placebo-day
TCF7L2 polymorphism,  
TT/TC/CC/U (%)
0/3/14/1 (0/17/78/5) 3/8/7/2 (19/38/33/10) 3/6/11/0 (15/30/55/0) 3/4/3/1 (27/37/27/9)
Baseline plasma glucagon 
(normoglycaemia) mean 
(s.d.) (nmol/L)
7.1 (1.9) 6.9 (2.2) 14 (3.7) 4.2 (0.7)
Peak plasma glucagon 
(hypoglycaemia) mean 
(s.d.) (nmol/L)
8.5 (2.9) 28 (11) 51 (21) 8.1 (3.0)
EPO, erythropoietin; PET, positron emission tomography; RAS, renin–angiotensin system; U, undetermined genotyping.
Table 3 Regression model with episodes of severe  
hypoglycaemia as dependent variable.
Change in episodes of SH per year per change  
in explanatory variable
Univariate P Multivariate P
Variable
Glucagon 
(pmol/L)
0.0 (−0.0 to 0.0) 0.83 0.0 (0.0–0.0) 0.96
TCF7L2 genotype
TT
TC
CC
−0.4 (−1.0 to 0.3)
−0.0 (−0.2 to 0.2)
–
0.26
0.89
−0.2 (−0.8 to 0.3)
−0.0 (−0.2 to 0.1)
–
0.42
0.71
Regression coefficients (95% confidence intervals) for concentrations of 
plasma glucagon and the TCF7L2 genotype (explanatory variables) in a 
generalized linear model (negative binomial distribution) with episodes 
of severe hypoglycaemia (SH) as dependent variable. The multivariate 
analyses are adjusted for age, duration of diabetes, C-peptide status, 
hypoglycaemia awareness status, HbA1c and serum ACE activity at 
baseline. The CC genotype serves as reference and is set to zero.  
ACE, Angiotensin-converting enzyme.
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age, duration of diabetes, C-peptide status, hypoglycaemia 
awareness status and HbA1c and serum ACE at baseline. 
Comparisons between the subgroups in Table 1 were done 
by one-way ANOVA, Kruskal–Wallis test or chi-square 
tests as appropriate.
Experimental study We report fasting plasma 
glucagon concentration at baseline (normoglycaemia) 
and during experimental hypoglycaemia. Baseline plasma 
glucagon concentration is calculated as the mean of two 
baseline values. In the RCT (37), baseline values from both 
arms of the cross-over study were pooled. Only data from 
the hypoglycaemic (and not normoglycaemic (control) or 
hypoxic) study days in the three other studies (34, 35, 
36) were included. Peak values of glucagon concentration 
were defined as the highest glucagon concentration 
measured during the hypoglycaemic clamp. We 
used a linear mixed model (SPSS: Analyze > Mixed 
Models > Linear > Continue) to compare the glucagon 
concentration during the experiments, the primary 
endpoint, in the three TCF7L2 polymorphism groups. 
Person-id was set as a random factor, and experimental 
condition (hypoglycaemia vs normoglycaemia), 
diabetes status (type 1 diabetes vs healthy) and TCF7L2 
polymorphism as fixed factors. Potentially, an interaction 
among diabetes status, experimental condition 
and TCF7L2 polymorphism was present. Therefore, 
interaction terms were constructed and included as 
fixed factors: experimental condition × diabetes status, 
experimental condition × TCF7L2 polymorphism and 
diabetes status × TCF7L2 polymorphism.
Calculations were performed with SPSS software 
package (version 11.0). We considered a two-tailed P value 
of less than 0.05 statistically significant.
Results
Epidemiological study
A total of 235 episodes of severe hypoglycaemia (0.96 
episodes per patient-year) were reported by 90 of 269 
patients (37%). The TCF7L2 alleles could be detected in 
245 of 269 patients (91%) and were distributed as follows: 
TT 5%, TC 36% and CC 59%. The mean incidences of 
severe hypoglycaemic episodes were 0.54 (0–5) in the 
TT group, 0.97 (0–15) in the TC group and 0.99 (0–16) 
episodes per patient-year in the CC group (Table 1).
The risk of severe hypoglycaemia was associated 
neither with the plasma glucagon concentration nor 
with the TCF7L2 genotype in univariate or multivariate 
regression analyses (Table 3). The hypoglycaemia aware-
ness status was not different in the three TCF7L2 genotype 
groups (P = 0.15, chi-square test) (Table 1). Mean plasma 
glucagon concentrations (± 1 s.d.) were 6.2 ± 4.8 pmol/L, 
4.9 ± 3.6 pmol/L and 4.7 ± 3.3 pmol/L in the TT, TC and 
CC groups, respectively (P = 0.70; Kruskal–Wallis test) 
(Table 1). Plasma glucagon concentrations did not differ 
between subjects with blood glucose concentrations equal 
to or above vs below 4 mmol/L at the time of glucagon 
measurement (P = 0.86), data not shown.
Figure 1
Mean values of plasma glucagon in 38 healthy adults (black lines) and  
27 people with type 1 diabetes (grey lines) divided according to the 
TCF7L2 genotypes TT, CT and CC before (normoglycaemia) and during 
experimental hypoglycaemia.
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Experimental study
Sixty-nine participants took part in the four studies. 
Among these, 40 were healthy adults and 29 had type 1 
diabetes. The TCF7L2 alleles could be detected in 65 (38 
healthy adults and 27 with type 1 diabetes) participants 
and were distributed as follows: TT 15%, TC 32% and CC 
53%. In the mixed model, there was no effect of TCF7L2 
polymorphism on plasma glucagon concentrations 
(P = 0.85 for main effect, P = 0.74 for the interaction 
term diabetes status × TCF7L2 polymorphism and 
P = 0.47 for the interaction term experimental condition 
and × TCF7L2 polymorphism). The interaction term 
diabetes status × experimental condition strongly affected 
glucagon concentration (F = 99.6, P = 2.0 × 10−14). The 
estimated means of plasma glucagon in healthy adults were 
11 (95% C.I. 7.5–14) nmol/L during normoglycaemia and 
39 (36–42) nmol/L during hypoglycaemia. The estimated 
means of glucagon in participants with type 1 diabetes 
were 5.0 (0.9–9.0) nmol/L during normoglycaemia and 
8.3 (4.0–13) nmol/L during hypoglycaemia (Fig. 1).
Discussion
We explored if variants of the TCF7L2 gene influence 
the risk of severe hypoglycaemia in a cohort of 245 
people with type 1 diabetes followed for one year in an 
observational prospective study of the occurrence of 
severe hypoglycaemia and risk markers for the events. 
In univariate and multivariate analyses, we found no 
significant relationship between the distribution of TCF7L2 
alleles and the risk of severe hypoglycaemia. Neither 
did we find any relationship between concentration of 
random measurements of plasma glucagon on one side 
and the risk of severe hypoglycaemia on the other.
Healthy carriers of the T allele of the TCF7L2 gene 
have been reported to have lower fasting glucagon 
concentrations compared with carriers of the C 
allele (26, 27, 28). Therefore, we hypothesised that 
carriers of the T allele could have a lower glucagon 
secretory capacity than carriers of the C allele, leading 
to diminished plasma glucagon responses during 
hypoglycaemia and thereby an increased risk of SH. We 
tested this in 38 healthy adults and 27 persons with 
type 1 diabetes and found no evidence supporting our a 
priori study hypothesis.
The strength of the epidemiological study is the 
large number of well-described patients with type 1 
diabetes followed prospectively for a relatively long 
time. Moreover, thorough gathering of data regarding 
episodes of severe hypoglycaemia (primary endpoint) 
and using a statistical model that deals with the much 
skewed distribution of episodes of severe hypoglycaemia 
is an advantage. Therefore, we find the results regarding 
the primary endpoint reliable. It is a possible limitation 
of the study that episodes of SH may be underreported, 
especially nocturnal episodes and especially by patients 
with recurrent episodes (32). Another limitation is the 
non-standardised measurement of plasma glucagon levels 
performed in non-fasting blood samples stored for several 
years. This may lead to both pre-analytical and analytical 
variation in plasma glucagon concentrations, thereby 
underestimating any possible role of glucagon. Moreover, 
our post hoc study was done in a population of patients 
with relatively long-standing type 1 diabetes, which is 
associated with a reduced secretory glucagon response to 
hypoglycaemia (20, 21). Potential differences in plasma 
glucagon levels due to TCF7L2 gene variations may be 
blurred by this.
The strength of the experimental studies is the 
relatively large number of persons studied during 
controlled hypoglycaemia. However, the methods 
to obtain hypoglycaemia and the subjects in the 
four studies were different, making pooling of data 
questionable. Nevertheless, we believe that the 
potential problem of using different methods to obtain 
hypoglycaemia in this post hoc study is insignificant 
as, in all four studies, a robust hypoglycaemic stimulus 
was obtained. Moreover, a possible influence of the 
TCF7L2 polymorphism should not depend on the 
method of inducing hypoglycaemia. The different 
subject characteristics of the populations in the four 
studies probably leads to greater variation in plasma 
glucagon concentrations rendering possible genotype-
related differences in plasma glucagon concentration 
more difficult to find, increasing the risk of a statistical 
type 2 error regarding the potential impact of the 
TCF7L2 polymorphism on plasma glucagon levels. 
However, analysing delta values of glucagon separately 
in participants with or without diabetes did not change 
the conclusions of this post hoc study.
The only hitherto consistently reported biomarkers 
of severe hypoglycaemia in type 1 diabetes are 
undetectable C-peptide levels (9, 4), low HbA1c 
(40, 41, 42) and high serum ACE activity (10, 11, 12, 13, 
14, 15). However, these markers only explain a minor 
proportion of the risk variation between subjects. We 
conclude that determination of TCF7L2 gene variations 
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and random measurements of plasma glucagon do not 
help predict episodes of severe hypoglycaemia in type 
1 diabetes. We also conclude that glucagon secretion 
during experimental hypoglycaemia in patients with and 
without type 1 diabetes is not affected by the TCF7L2 gene 
polymorphism. These results add up to the complicated 
picture of glucagon function in glucose homeostasis. 
Although the TCF7L2 gene polymorphism seems to 
affect glucagon secretion during normoglycaemia 
and hyperglycaemia in normal man and patients with 
type 2 diabetes, the response to hypoglycaemia both 
in normal man and patients with type 1 diabetes is 
unaffected by this polymorphism. However, due to the 
limitations of the study (pre-analytical and analytical 
variation in plasma glucagon concentrations), we need 
studies to validate the effect of TCF7L2 genotypes 
on glucagon levels and risk of severe episodes of 
hypoglycaemia in type 1 diabetes. Finding robust risk 
factors for the identification of patients at high risk 
of severe hypoglycaemia would be beneficial in daily 
diabetes management. Moreover, it could improve the 
understanding of the physiology of hypoglycaemia.
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